老年晚期胰腺癌患者应用替吉奥单药化疗的疗效分析  

Analysis of curative effect by single tegafur gimeracil oteracil chemotherapy for senile advanced pancreatic cancer patients

作　　者：吴爽[1] 张咏梅[1] 范丽昕[1] 

机构地区：[1]辽宁省大连市第三人民医院肿瘤科,116033

出　　处：《中国现代药物应用》2016年第21期11-12,共2页Chinese Journal of Modern Drug Application

摘　　要：目的观察老年晚期胰腺癌患者一线选择替吉奥单药口服化疗的疗效及安全性。方法回顾性分析36例老年晚期胰腺癌患者,一线采用替吉奥单药化疗。每2个周期进行疗效及不良反应评估。结果所有患者均完成2周期以上化疗,完全缓解0例,部分缓解15例,疾病稳定16例,疾病进展5例,客观有效率41.7%,疾病控制率86.1%。随访6个月生存率为58.3%,1年生存率为27.8%。不良反应集中表现为Ⅰ-Ⅱ度的骨髓抑制、恶心呕吐及肝功能异常,对症处理可缓解。结论替吉奥单药口服治疗老年中晚期胰腺癌疗效确切,不良反应小,耐受性好。Objective To observe curative effect and safety by single tegafur gimeracil oteracil chemotherapy for senile advanced pancreatic cancer patients. Methods A retrospective analysis was made on 36 senile advanced pancreatic cancer patients, who received single tegafur gimeracil oteracil chemotherapy. Their curative effect and adverse reactions were evaluated in every 2 cycles. Results All patients received over 2 chemotherapy cycles, along with 0 complete remission case, 15 partial remission cases, 16 stable disease cases and 5 disease progression cases. Their objective effective rate was 41.7%, disease control rate was 86.1%, 6-month survival rate in follow-up was 58.3%, and 1-year survival rate was 27.8%. Their adverse reactions included degree Ⅰ - Ⅱ myelosuppression, nausea, vomiting, and liver dysfunction, which were relieved by symptomatic treatment. Conclusion Oral administration of tegafur gimeracil oteracil provides excellent curative effect in treating senile advanced pancreatic cancer, along with few adverse reactions and good tolerance.

关 键 词：替吉奥 胰腺癌 老年 疗效 

分 类 号：R735.9[医药卫生—肿瘤]